We have previously shown that CRIS‐C patient‐derived xenografts (PDX) respond to EGFR inhibition (cetuximab) 8, which was further validated using tumour profiles from a phase II metastatic CRC study 22. The gene discussed is EGFR; the disease is colorectal carcinoma.